This MINISO Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

  • Goldman Sachs analyst David Roman initiated coverage on Tandem Diabetes Care, Inc. TNDM with a Neutral rating and announced a price target of $46. Tandem Diabetes Care shares fell 1.7% to close at $40.46 on Thursday. See how other analysts view this stock.
  • Raymond James analyst Laura Prendergast initiated coverage on Mural Oncology plc MURA with a Strong Buy rating and announced a price target of $18. Mural Oncology shares gained 2.6% to close at $3.20 on Thursday. See how other analysts view this stock.
  • Canaccord Genuity analyst George Gianarikas initiated coverage on ASP Isotopes Inc. ASPI with a Buy rating and announced a price target of $4.5. ASP Isotopes shares gained 11.1% to close at $3.01 on Thursday. See how other analysts view this stock.
  • JP Morgan analyst Michael Mueller initiated coverage on Curbline Properties Corp. CURB with a Overweight rating and announced a price target of $25. Curbline Properties shares gained 4.3% to close at $22.60 on Thursday. See how other analysts view this stock.
  • Citigroup analyst Xiaopo Wei initiated coverage on MINISO Group Holding Limited MNSO with a Buy rating and announced a price target of $26.8. MINISO Group shares fell 0.2% to close at $18.96 on Thursday. See how other analysts view this stock.

Considering buying MNSO stock? Here’s what analysts think:

Loading...
Loading...

Read Next:

MNSO Logo
MNSOMINISO Group Holding Ltd
$17.89-2.56%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
23.45
Growth
Not Available
Quality
Not Available
Value
76.00
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Comments
Loading...